Then, a combination of tremelimumab and durvalumab received approval in the United States for treating unresectable hepatocellular carcinoma in 2022 [31], signifying the clinical transition of combining anti-CTLA-4 and anti-PD-1 antibodies. The gene discussed is CTLA4; the disease is hepatocellular carcinoma.